Insights

Patexia Insight 213: The Revlimid Dispute From Antitrust Battles to Patent Litigation

Revlimid (lenalidomide) , developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma since its FDA approval in 2005. The drug has also been at the center of complex legal…